Congenital Heart Disease-Pipeline Insights, 2017

Orbis Research released a new research report of 60 pages on title “Congenital Heart Disease-Pipeline Insights, 2017” Report Focuses on Market, Status and Forecast, by Players, Types and Applications’ with detailed analysis, forecast and strategies.

“Congenital Heart Disease-Pipeline Insights, 2017”, report provides in depth insights on the pipeline drugs and their development activities around the Congenital Heart Disease. The Report covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details.

Hurry up Limited Period Offer- We are Currently Offering Discount on this report: Orbis Research
(Discounted Price Details: Get Flat 15% on Single User License, Flat 25% on Site License & Flat 30% on Enterprise Licence)

Report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for Congenital Heart Disease. DelveInsight’s Report also assesses the Congenital Heart Disease therapeutics by Monotherapy, Combination products, Molecule type and Route of Administration.

Browse Full Report with TOC: http://www.orbisresearch.com/reports/index/congenital-heart-disease-pipeline-insights-2017

Scope
• The report provides competitive pipeline landscape of Congenital Heart Disease
• The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
• Coverage of the Congenital Heart Disease pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
• The report reviews key players involved in the therapeutics development for Congenital Heart Disease and also provide company profiling
• The report also gives the information of dormant and discontinued pipeline projects
• Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
• Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type

Place Purchase Order for this Report@ http://www.orbisresearch.com/contact/purchase/214694

Table of Contents
Congenital Heart Disease Overview
Congenital Heart Disease Pipeline Therapeutics
Congenital Heart Disease Therapeutics under Development by Companies
Congenital Heart Disease Filed and Phase III Products
Comparative Analysis
Congenital Heart Disease Phase II Products
Comparative Analysis
Congenital Heart Disease Phase I and IND Filed Products
Comparative Analysis
Congenital Heart Disease Discovery and Pre-Clinical Stage Products
Comparative Analysis
Drug Candidate Profiles
Congenital Heart Disease – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Congenital Heart Disease – Discontinued Products
Congenital Heart Disease – Dormant Products
Companies Involved in Therapeutics Development for Congenital Heart Disease
Appendix
Methodology
Contact Us
Disclaimer

List of Tables:
Number of Products under Development for Congenital Heart Disease, 2017
Number of Products under Development by Companies
Comparative Analysis by Filed and Phase III Products, 2017
Comparative Analysis Phase II Products, 2017
Comparative Analysis Phase I and IND Filed Products, 2017
Comparative Analysis Discovery and Pre-Clinical Stage Products, 2017
Drug Candidates Profiles
Congenital Heart Disease Assessment by Monotherapy Products
Congenital Heart Disease Assessment by Combination Products
Congenital Heart Disease Assessment by Route of Administration
Congenital Heart Disease Assessment by Stage and Route of Administration
Congenital Heart Disease Assessment by Molecule Type
Congenital Heart Disease Assessment by Stage and Molecule Type
Congenital Heart Disease Therapeutics – Discontinued Products
Congenital Heart Disease Therapeutics – Dormant Products
Products under Development by Companies, 2017
Number of Products under Development for Congenital Heart Disease, 2017
Filed and Phase III Products, 2017
Phase II Products, 2017
Phase I and IND Filed Products, 2017
Discovery and Pre-Clinical Stage Products, 2017
Congenital Heart Disease Assessment by Monotherapy Products
Congenital Heart Disease Assessment by Combination Products
Congenital Heart Disease Assessment by Route of Administration
Congenital Heart Disease Assessment by Stage and Route of Administration
Congenital Heart Disease Assessment by Molecule Type
Congenital Heart Disease Assessment by Stage and Molecule Type

Orbis Research is a single point aid for all your Market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customised reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialisation. This helps our clients to map their needs and we produce the perfect required Market research study for our clients.

Hector Costello
Senior Manager – Client Engagements
4144N Central Expressway,
Suite 600, Dallas,
Texas - 75204, U.S.A.
Phone No.: +1 (214) 884-6817; +912064101019
Email ID: sales@orbisresearch.com

This release was published on openPR.